In recent years, since the rapid development of immunological checkpoint therapy such as CTLA-4 (4) and PD-1 (5) in AML, TME has attracted more and more attention as a key cell environment for immune cells, extracellular matrix molecules, and stromal cells (6, 7). Here, CTLA4 is linked to acute myeloid leukemia.